Switching inhibitor class overcomes crizotinib resistance in a MET fusion-positive NSCLC with a novel acquired MET G1090A mutation.
Yonina R. Murciano-Goroff,Srinivasaraghavan Kannan,Jason C. Chang,Ryma Benayed,Ilya Blokhin,Natasha Rekhtman,Ann Elizabeth Sisk, Jaime Gibson, Lia Judka, Lauren Kaplanis, Madeline Merrill, Erica Sgroe,Chandra S. Verma,Alexander Drilon,Emiliano Cocco CANCER RESEARCH（2022）
AI 理解论文
溯源树
样例
